Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TetraLogic Pharmaceuticals Corp TLOG

Healthcare Biotechnology
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two... see more

Recent & Breaking News (GREY:TLOG)

TetraLogic Announces Public Offering of Common Stock

GlobeNewswire April 30, 2015

TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B

GlobeNewswire April 21, 2015

TetraLogic to Present at the 14th Annual Needham Healthcare Conference

GlobeNewswire April 9, 2015

TetraLogic Reports 2014 Financial Results and Provides Clinical Programs Update

GlobeNewswire February 26, 2015

TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma

GlobeNewswire December 18, 2014

TetraLogic Provides Update on Ovarian Cancer Study

GlobeNewswire December 16, 2014

TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 56th Annual American Society of Hematology Annual Meeting

GlobeNewswire December 4, 2014

TetraLogic to Participate in Two Conferences in December

GlobeNewswire December 2, 2014

TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B

GlobeNewswire November 10, 2014

TetraLogic Pharmaceuticals Announces Appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as New Directors

GlobeNewswire November 7, 2014

TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update

GlobeNewswire November 5, 2014

TetraLogic Pharmaceuticals to Host Investor Forum on November 10, 2014

GlobeNewswire November 3, 2014

TetraLogic Pharmaceuticals to Present Data From Pre-Clinical Studies With Hepatitis B at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses

GlobeNewswire August 27, 2014

TetraLogic Announces Closing of $47 Million Convertible Senior Notes Offering

GlobeNewswire June 24, 2014

TetraLogic Announces Pricing of $47 Million Offering of Convertible Notes

GlobeNewswire June 17, 2014

TetraLogic Pharmaceuticals Announces Conference Call With Dr. Marc Pellegrini of the Walter and Eliza Hall Institute of Medical Research to Discuss TetraLogic Infectious Disease Program

GlobeNewswire June 13, 2014

TetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant's Breadth of Activity in Models of Infectious Disease

GlobeNewswire June 9, 2014

TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting

GlobeNewswire May 28, 2014

TetraLogic Pharmaceuticals Announces Selection of Phase 2 Dose for Randomized Clinical Study of Birinapant in Combination With Azacitidine in Naive Patients With Higher Risk Myelodysplastic Syndromes (MDS)

GlobeNewswire May 27, 2014

TetraLogic to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference

GlobeNewswire May 8, 2014